GBM (glioblastoma multiforme) is the most common and aggressive brain tumor. To date, treatment options for glioblastoma recurrence are lacking. Recently, REGOMA trial showed the superiority of regorafenib to lomustine in patients with first glioblastoma recurrence. We report an excellent response to three months treatment with regorafenib, in a patient who presented a rapid progression after the end of post operative radio-chemotherapy and after only one cycle of adjuvant TMZ (Temozolomide).
Regorafenib in glioblastoma recurrence: A case report / Detti B.; Scoccianti S.; Lucidi S.; Maragna V.; Teriaca M.A.; Ganovelli M.; Desideri I.; Lorenzetti V.; Scoccimarro E.; Greto D.; Livi L.. - In: CANCER TREATMENT AND RESEARCH COMMUNICATIONS. - ISSN 2468-2942. - ELETTRONICO. - 26:(2021), pp. 0-0. [10.1016/j.ctarc.2020.100263]
Regorafenib in glioblastoma recurrence: A case report
Detti B.;Scoccianti S.;Lucidi S.;Maragna V.;Teriaca M. A.;Ganovelli M.;Desideri I.;Lorenzetti V.;Scoccimarro E.;Greto D.;Livi L.
2021
Abstract
GBM (glioblastoma multiforme) is the most common and aggressive brain tumor. To date, treatment options for glioblastoma recurrence are lacking. Recently, REGOMA trial showed the superiority of regorafenib to lomustine in patients with first glioblastoma recurrence. We report an excellent response to three months treatment with regorafenib, in a patient who presented a rapid progression after the end of post operative radio-chemotherapy and after only one cycle of adjuvant TMZ (Temozolomide).
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
